Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the virologic response to 12 weeks of treatment with ABT-493/ABT-530 by determining the percentage of subjects who achieved a sustained virologic response at 12 weeks post-treatment (SVR12) and to evaluate safety of ABT-493/ABT-530 in adults with chronic HCV genotype 1 – 6 infection with chronic renal impairment.
Critère d'inclusion
- Chronic HCV Genotype 1-6 Infection